Journey Medical Corporation (Nasdaq:DERM), a pharmaceutical company with a focus on dermatological conditions, on Monday announced the launch and initial distribution of Emrosi, a 40 mg modified-release minocycline hydrochloride capsule, for the treatment of inflammatory lesions of rosacea in adults.
The product is available through specialty pharmacy chains.
Approved by the US Food and Drug Administration in November 2024, Emrosi is the lowest-dose oral minocycline available for rosacea treatment. Clinical trials demonstrated that Emrosi provides superior clinical outcomes compared to Oracea and placebo, while maintaining a comparable safety profile.
The first prescriptions of Emrosi have been filled.
Claude Maraoui, CEO of Journey Medical, said that the launch of Emrosi represents a major milestone for the company and reinforces its commitment to improving the quality of life for individuals with dermatological conditions.
DATROWAY receives US priority review for first-line metastatic triple negative breast cancer
Lupin launches Dasatinib tablets in US market
Natera submits Signatera CDx PMA to FDA for bladder cancer use
Pharming receives FDA complete response letter for paediatric Joenja application
Trace Biosciences' IND application for nerve-specific imaging agent approved by FDA
Frontage expands early phase clinical research capabilities across US and China
MicuRx Pharmaceuticals' IND application for MRX-5 cleared by FDA
FDA approves Tenpoint Therapeutics' YUVEZZI as first dual-agent eye drop for presbyopia
Summit Therapeutics' BLA for ivonescimab in EGFR-mutated NSCLC accepted by FDA
WuXi Biologics collaborates with Sinorda Biomedicine for antibody development
Biogen's litifilimab receives FDA Breakthrough Therapy Designation for CLE
Glaukos receives FDA approval for repeat administration of iDose TR
Guerbet's contrast agent Elucirem approved by European Commission in children from birth
Spine Innovation's LOGIC Titanium Implant System receives US FDA 510(k) market approval